Healthcare
Live Price
Offline$0.4696
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) is a Healthcare stock with a market cap of $13.56B and listed on OTC. The stock last traded around $0.47 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +3.8%, EPS growth of -45.5%, a dividend yield of 2.3%. What stands out right now is revenue +3.8%, EPS -45.5%, free cash flow -20.1% with operating margin 12.3% and ROIC 3.8%. The dividend is present but secondary, with a yield around 2.3%. Valuation already assumes a fairly strong business story at P/E 41.9 and price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SHEZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHEZF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHEZF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHEZF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.4B
-11.1% YoY
FY Net Income
$240.8M
-66.9% YoY
Free Cash Flow
-$200.5M
+79.5% YoY
Revenue Growth
+3.8%
EPS Growth
-45.5%
Gross Margin
33.5%
Net Margin
7.0%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.5B | 5.3B | 5.4B | 7.2B | 6.4B |
| Gross Profit | 1.7B | 1.8B | 945M | 2.3B | 2.0B |
| Operating Income | 636M | 741M | -861M | 829M | 227M |
| EBITDA | 847M | 1.2B | -320M | 1.4B | 731M |
| Net Income | 349M | 647M | -783M | 727M | 241M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.3B | 1.7B | 1.9B | 2.1B | 2.9B |
| Total Assets | 16.6B | 17.3B | 19.2B | 20.8B | 19.1B |
| Total Liabilities | 4.6B | 5.1B | 7.2B | 8.4B | 7.6B |
| Shareholder Equity | 12.0B | 12.1B | 11.9B | 12.3B | 11.4B |
| Total Debt | 2.1B | 3.0B | 3.8B | 6.5B | 5.7B |
| Net Debt | 763M | 1.3B | 1.9B | 4.3B | 2.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+99.1% YoY
Capital Expenditures
194M
+12.8% YoY
Free Cash Flow
200M
+79.5% YoY
Key ratios
Gross Margin
33.5%
Operating Margin
12.3%
Net Margin
7.0%
ROE
3.1%
Debt / Equity
0.23x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.